.Net Biotechnology Development Software 
GeekWire
FEBRUARY 15, 2022
Adaptive Biotechnologies , which develops technology to assess the immune response, posted $154.3 Net loss for 2021 came in at $207.3 million in the fourth quarter, up 26%, with a net loss of $61.4 Tests for five autoimmune and inflammatory conditions, including Crohn’s disease, are in earlier stages of development.
GeekWire
AUGUST 23, 2021
In a region better known for its tech startups and legions of software engineers, it’s biotech companies that have helped lead a recent IPO boom in the state of Washington, accounting for eight of 11 firms joining the public markets via a traditional IPO over the past year. based biotech company went public. Absci Photo).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeekWire
SEPTEMBER 17, 2020
Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. Formerly known as M3 Biotechnology, the company is led by Dr. Leen Kawas , a 35-year-old CEO who will be the first woman to guide a company to an initial public offering in Washington state in more than two decades.
GeekWire
AUGUST 26, 2020
The Seattle biotech filed initial IPO paperwork Wednesday, a surprising move that would give the company additional capital to develop its therapies for brain diseases. Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. In its IPO paperwork, Athira reports a net loss of $5.2
GeekWire
SEPTEMBER 18, 2020
It’s the latest privately-held company to test the public markets amid a rush of IPOs in recent months, particularly in biotech and software , despite the ongoing pandemic. Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. The stock was up slightly in Friday morning trading.
Trends in the Living Networks
MARCH 23, 2011
Their joint work on a process for cloning genes in microorganisms resulted in three patents that formed the foundation of the nascent biotechnology industry. Do you need to come up with startlingly new and different ideas, or do you have to develop the seed of an idea into something useful and workable?
GeekWire
FEBRUARY 8, 2021
Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology , a Seattle-based biotech startup led by Isilon co-founder Sujal Patel , is the latest company to go public using a special purpose acquisition company, or SPAC. Nautilus Photo). It values the company at $900 million.
Expert insights. Personalized for you.
98 
Let's personalize your content